Nalaganje...
Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer
Chemotherapy has historically proven toxic and ineffective for the treatment of metastatic hormone-refractory prostate cancer (HRPC), a disease with substantial morbidity and mortality. Progress has been made in symptom relief, and the combination of mitoxantrone and prednisone is considered the pal...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MedReviews, LLC
2003
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1502327/ https://ncbi.nlm.nih.gov/pubmed/16986041 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|